Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|May 15, 2014
- Pharmaceutical Technology-05-15-2014
- Volume 2014 eBook
- Issue 2
Continuous Bioprocessing Challenges
What challenges do biopharmaceutical manufacturers face when deciding to move from a fed batch process to a continuous process?
Advertisement
What challenges do biopharmaceutical manufacturers face when deciding to move from a fed batch process to a continuous process? Stéphanie Dubois, cell culture laboratory manager and application specialist at Pall Life Sciences, describes challenges and explains how alternative types of perfusion bioreactors can simplify the process.
Download
.
Articles in this issue
over 12 years ago
Potential Benefits Drive Interest in Continuous Manufacturingover 12 years ago
Optimizing the Sterilization of Liquids in Sealed Containersover 12 years ago
Using Modular Systems in Biopharmaceutical Manufacturingover 12 years ago
Determining Protein Oxidation Induced During Fill-Finish Operationsover 12 years ago
Single-Use Technology in Parenteral Fill/FinishAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Complying with International Pharmacopoeias
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5